PepGen Inc.(PEPG),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

PEPG PepGen Inc.

Market Closed 08-28 16:00:00 EDT

3.08

+0.01

+0.33%

盘后3.08

+0.000.00%

19:30 EDT

High3.13	Low2.98	Vol484.91K
Open3.05	D1 Closing3.07	Amplitude4.89%
Mkt Cap212.88M	Tradable Cap111.30M	Total Shares69.12M
T/O1.48M	T/O Rate1.34%	Tradable Shares36.14M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"PEPG","market":"US","secType":"STK","nameCN":"PepGen Inc.","latestPrice":3.08,"timestamp":1787947200000,"preClose":3.07,"halted":0,"volume":484906,"hourTrading":{"tag":"盘后","latestPrice":3.08,"preClose":3.08,"latestTime":"19:30 EDT","volume":600,"amount":1850.2891,"timestamp":1787959806303,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.0032573289902280886,"floatShares":36136100,"shares":69115292,"eps":-1.190299,"marketStatus":"Market Closed","change":0.01,"latestTime":"08-28 16:00:00 EDT","open":3.05,"high":3.13,"low":2.98,"amount":1478958.6449024,"amplitude":0.04886,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.190299,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1788163200000},"marketStatusCode":7,"adr":0,"listingDate":1651809600000,"exchange":"NASDAQ","adjPreClose":3.07,"preHourTrading":{"tag":"盘前","latestPrice":3.0665,"preClose":3.07,"latestTime":"08:50 EDT","volume":2446,"amount":7492.8670224,"timestamp":1787921432034,"change":-0.0035,"changeRate":-0.00114,"amplitude":0.02101},"postHourTrading":{"tag":"盘后","latestPrice":3.08,"preClose":3.08,"latestTime":"19:30 EDT","volume":600,"amount":1850.2891,"timestamp":1787959806303,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.6797447812850002,"impliedVol":0.3198,"impliedVolPercentile":0.0558},"requestUrl":"/m/hq/s/PEPG","defaultTab":"news","newsList":[{"id":"2657637115","title":"PepGen Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2657637115","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657637115?lang=en_us&edition=fundamental","pubTime":"2026-08-06 21:58","pubTimestamp":1786024710,"startTime":"0","endTime":"0","summary":"PepGen Inc. reports results for the quarter ended June 30 - Earnings SummaryPepGen Inc.PEPG.OQreported a quarterly adjusted loss of 26 cents per share for the quarter ended June 30, higher than the sa","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nL8N443253:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PEPG","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657637356","title":"Analysts’ Opinions Are Mixed on These Healthcare Stocks: GoodRx Holdings (GDRX), Xencor (XNCR) and PepGen Inc. (PEPG)","url":"https://stock-news.laohu8.com/highlight/detail?id=2657637356","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657637356?lang=en_us&edition=fundamental","pubTime":"2026-08-06 21:40","pubTimestamp":1786023641,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on GoodRx Holdings (GDRX), Xencor (XNCR) and PepGen I...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-goodrx-holdings-gdrx-xencor-xncr-and-pepgen-inc-pepg-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-goodrx-holdings-gdrx-xencor-xncr-and-pepgen-inc-pepg-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","BK4137","GDRX","HCSG","LU0128526141.USD","PEPG","BK4167","XLV","XNCR","LABU","LU0029874061.USD","BK4581","XBI","BK4585","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657863624","title":"PepGen Q2 EPS $(0.26) Beats $(0.29) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2657863624","media":"Benzinga Earnings","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657863624?lang=en_us&edition=fundamental","pubTime":"2026-08-06 20:04","pubTimestamp":1786017841,"startTime":"0","endTime":"0","summary":"PepGen (NASDAQ:PEPG) reported quarterly losses of $(0.26) per share which beat the analyst consensus estimate of $(0.29) by 10.34 percent. This is a 62.86 percent increase over losses of $(0.70) per share from the same","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/08/60991385/pepgen-q2-eps-0-26-beats-0-29-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PEPG","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657350856","title":"PepGen Q2 Net Loss Narrows as Expenses Fall","url":"https://stock-news.laohu8.com/highlight/detail?id=2657350856","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657350856?lang=en_us&edition=fundamental","pubTime":"2026-08-06 19:52","pubTimestamp":1786017130,"startTime":"0","endTime":"0","summary":"PepGen Q2 net loss narrows as expenses fallOverviewBiotechnology company's Q2 net loss narrowed yr/yr as operating expenses declinedCompany ended Q2 with $117.2 mln in cash, sufficient to fund operati","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nL1N4430LC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DSGN","BK4505","BK4139","PEPG","TRDA","BK4539","BMEA","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657635812","title":"PepGen Advances PGN-Edodm1 into 12.5 Mg/kg Cohort in Phase 2 Freedom2-DM1 Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2657635812","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657635812?lang=en_us&edition=fundamental","pubTime":"2026-08-06 19:34","pubTimestamp":1786016095,"startTime":"0","endTime":"0","summary":"PepGen advances PGN-EDODM1 into 12.5 mg/kg cohort in Phase 2 FREEDOM2-DM1 trialPepGen will move PGN-EDODM1 into the highest-dose cohort in its Phase 2 FREEDOM2-DM1 study following a DSMB safety review","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nNDL5YDqYV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PEPG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657633075","title":"PepGen Q2 FY26 Net Loss Narrows 22.84% to $17.81 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2657633075","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657633075?lang=en_us&edition=fundamental","pubTime":"2026-08-06 19:33","pubTimestamp":1786015983,"startTime":"0","endTime":"0","summary":"PepGen Q2 FY26 net loss narrows 22.84% to $17.81 millionPepGen posted a net loss of USD 17.81 million, narrowing from USD 23.09 million a year earlier.Operating loss narrowed to USD 18.94 million from","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nNDL89sqWF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PEPG","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657963307","title":"PepGen Q2 EPS USD -0.26","url":"https://stock-news.laohu8.com/highlight/detail?id=2657963307","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657963307?lang=en_us&edition=fundamental","pubTime":"2026-08-06 19:33","pubTimestamp":1786015980,"startTime":"0","endTime":"0","summary":"BRIEF-PepGen Q2 EPS USD -0.26Aug 06 (Reuters) - PepGen Q2 operating income USD -18.939 million.Q2 operating expenses USD 18.939 millionQ2 net income USD -17.812 million","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nPLXK5GZG5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PEPG","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657063306","title":"PepGen - Cash of $117.20 Mln as of June 30, 2026; Funds Operations into Q4 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2657063306","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657063306?lang=en_us&edition=fundamental","pubTime":"2026-08-06 19:32","pubTimestamp":1786015920,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nPLXK5GZG5:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PEPG","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657633011","title":"Press Release: PepGen Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2657633011","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657633011?lang=en_us&edition=fundamental","pubTime":"2026-08-06 19:32","pubTimestamp":1786015920,"startTime":"0","endTime":"0","summary":"--  PepGen has fully enrolled the 10 mg/kg MAD cohort of FREEDOM2,with 7 of 8 participants having completed dosing. Data from this. cohort is on track to be reported in November.--  Based on the review of available safety data from the 10 mg/kg. MAD cohort and the open-label extension  study, an. advancing the FREEDOM2 trial into the third and highest dose. cohort . The DSMB also approved dose escalation in the. OLE study from 5 mg/kg to 10 mg/kg. Read the full release here.--  Results from the 12.5 mg/kg cohort of FREEDOM2 are expected in. the first half of 2027. Pending results from Cohorts 2 and 3,PepGen plans to engage with regulators in an end of Phase 2 . meeting to discuss plans for the registrational program.OLE, 6 of 8 participants from the 5 mg/kg FREEDOM2 cohort have","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4081","PEPG","BK4139","EMA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657635368","title":"PepGen - no Cumulative Toxicity or Treatment Discontinuations Reported at 5 Mg/Kg and 10 Mg/Kg","url":"https://stock-news.laohu8.com/highlight/detail?id=2657635368","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657635368?lang=en_us&edition=fundamental","pubTime":"2026-08-06 19:30","pubTimestamp":1786015801,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nTUA7TNQTX:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","PEPG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657635352","title":"PepGen - to Report 10 Mg/Kg Freedom2 Cohort Results in November","url":"https://stock-news.laohu8.com/highlight/detail?id=2657635352","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657635352?lang=en_us&edition=fundamental","pubTime":"2026-08-06 19:30","pubTimestamp":1786015801,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nTUA7TNQTX:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","PEPG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657633277","title":"PepGen to Advance Pgn-Edodm1 into Highest Dose Cohort in Phase 2 Freedom2-Dm1 Study Following Dsmb Review","url":"https://stock-news.laohu8.com/highlight/detail?id=2657633277","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657633277?lang=en_us&edition=fundamental","pubTime":"2026-08-06 19:30","pubTimestamp":1786015801,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nTUA7TNQTX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","PEPG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656374158","title":"PepGen Inc Expected to Post a Loss of 29 Cents a Share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2656374158","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656374158?lang=en_us&edition=fundamental","pubTime":"2026-08-03 21:33","pubTimestamp":1785763986,"startTime":"0","endTime":"0","summary":"PepGen Inc <PEPG.OQ> expected to post a loss of29cents a share - Earnings PreviewPepGen IncPEPG.OQPEPG.Ois expected to  show no change in quarterly revenue when it reports  results on August 5 (estima","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260803:nL8N4401GS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PEPG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645070343","title":"PepGen shareholders ratify KPMG as independent auditor for 2026 fiscal year","url":"https://stock-news.laohu8.com/highlight/detail?id=2645070343","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645070343?lang=en_us&edition=fundamental","pubTime":"2026-06-23 04:30","pubTimestamp":1782160259,"startTime":"0","endTime":"0","summary":"PepGen held its annual shareholder meeting on June 18, 2026.Shareholders selected three Class I directors for terms running to the 2029 annual meeting.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PepGen Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 22, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260622:nNDLbPLhlr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PEPG","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645092919","title":"Analysts Are Bullish on These Healthcare Stocks: PepGen Inc. (PEPG), CG Oncology, Inc. (CGON)","url":"https://stock-news.laohu8.com/highlight/detail?id=2645092919","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645092919?lang=en_us&edition=fundamental","pubTime":"2026-06-21 15:30","pubTimestamp":1782027005,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on PepGen Inc. (PEPG) and CG Oncology, Inc. (CGON) with...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-pepgen-inc-pepg-cg-oncology-inc-cgon-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-pepgen-inc-pepg-cg-oncology-inc-cgon-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","PEPG","CGON"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643765808","title":"PepGen Initiated at Buy by Craig-Hallum","url":"https://stock-news.laohu8.com/highlight/detail?id=2643765808","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643765808?lang=en_us&edition=fundamental","pubTime":"2026-06-16 22:44","pubTimestamp":1781621040,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/PEPG/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 16, 2026 10:44 ET (14:44 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PEPG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643675161","title":"Craig-Hallum Initiates PepGen at Buy With $11 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2643675161","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643675161?lang=en_us&edition=fundamental","pubTime":"2026-06-16 19:21","pubTimestamp":1781608879,"startTime":"0","endTime":"0","summary":"PepGen (PEPG) has an average rating of buy and mean price target of $10.14, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major banks and re","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","PEPG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639621318","title":"Analysts Have Conflicting Sentiments on These Healthcare Companies: PepGen Inc. (PEPG) and West Pharmaceutical Services (WST)","url":"https://stock-news.laohu8.com/highlight/detail?id=2639621318","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639621318?lang=en_us&edition=fundamental","pubTime":"2026-05-29 18:40","pubTimestamp":1780051243,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on PepGen Inc. (PEPG) and West Pharmaceutical Services (WST). PepGen...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-pepgen-inc-pepg-and-west-pharmaceutical-services-wst-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-pepgen-inc-pepg-and-west-pharmaceutical-services-wst-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XBI","LU0029874061.USD","LU0345774391.USD","BK4567","LU0128526141.USD","BK4121","PEPG","LABU","LU0106261612.USD","BK4581","BK4585","BK4139","HCSG","IE00B64QTZ34.USD","IE00BFXG0V08.USD","LU0345774631.USD","BK4588","XLV","WST","BK4504","BK4137","LU0012050646.USD","IE00BYQQ9H92.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637397211","title":"Analysts’ Opinions Are Mixed on These Healthcare Stocks: HUTCHMED (HCM), PepGen Inc. (PEPG) and Glaukos (GKOS)","url":"https://stock-news.laohu8.com/highlight/detail?id=2637397211","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637397211?lang=en_us&edition=fundamental","pubTime":"2026-05-22 17:10","pubTimestamp":1779441059,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on HUTCHMED (HCM), PepGen Inc. (PEPG) and Glaukos (GK...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-hutchmed-hcm-pepgen-inc-pepg-and-glaukos-gkos-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-hutchmed-hcm-pepgen-inc-pepg-and-glaukos-gkos-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XBI","HCM","LU0029874061.USD","BK4007","LU0128526141.USD","PEPG","LABU","BK4581","BK4585","BK4139","HCSG","GKOS","BK4082","IE0009354923.USD","BK4548","BK4588","LU1878469433.USD","XLV","BK4137","LU2065731478.USD","BK4531"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637938084","title":"PepGen presents FREEDOM-DM1 trial data for PGN-EDODM1 at IDMC-15","url":"https://stock-news.laohu8.com/highlight/detail?id=2637938084","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637938084?lang=en_us&edition=fundamental","pubTime":"2026-05-21 19:00","pubTimestamp":1779361242,"startTime":"0","endTime":"0","summary":"PepGen flagged new clinical data from its PGN-EDODM1 program for myotonic dystrophy type 1, with results set for presentation at the 15th International Myotonic Dystrophy Consortium meeting on May 26-30, 2026, in Quebec.The company plans to show analyses of individual patient mis-splicing, supported by natural history work intended to frame how mis-splicing changes in DM1.A separate poster is slated to highlight the FREEDOM-DM1 trial, describing strong splicing correction from single doses of PGN-EDODM1 with an acceptable safety profile.Additional single-dose data, alongside initial multiple ascending dose data, are scheduled for a May 26, 2026 Pharma Day presentation.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PepGen Inc. publishe","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260521:nNDL2GgzS6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PEPG"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.pepgen.com","stockEarnings":[{"period":"1week","weight":-0.0191},{"period":"1month","weight":0.8012},{"period":"3month","weight":1.0533},{"period":"6month","weight":-0.5048},{"period":"1year","weight":1.5246},{"period":"ytd","weight":-0.5269}],"compareEarnings":[{"period":"1week","weight":0.0047},{"period":"1month","weight":0.0547},{"period":"3month","weight":0.017},{"period":"6month","weight":0.1215},{"period":"1year","weight":0.1856},{"period":"ytd","weight":0.1282}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. Its lead product candidate is PGN-EDO51, an EDO peptide that is in Phase 2 clinical trial to treat Duchenne muscular dystrophy (DMD) patients. The company is also developing PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 1 clinical trial for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. PepGen Inc. was founded in 2018 and is based in Boston, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.057082},{"month":2,"riseRate":0.75,"avgChangeRate":0.580465},{"month":3,"riseRate":0,"avgChangeRate":-0.400307},{"month":4,"riseRate":0.5,"avgChangeRate":0.028304},{"month":5,"riseRate":0.25,"avgChangeRate":0.041771},{"month":6,"riseRate":0.2,"avgChangeRate":-0.115638},{"month":7,"riseRate":0.4,"avgChangeRate":-0.054781},{"month":8,"riseRate":0.4,"avgChangeRate":0.06784},{"month":9,"riseRate":0.25,"avgChangeRate":0.658187},{"month":10,"riseRate":0.75,"avgChangeRate":0.035806},{"month":11,"riseRate":0.5,"avgChangeRate":0.080021},{"month":12,"riseRate":0.5,"avgChangeRate":0.010709}],"exchange":"NASDAQ","name":"PepGen Inc.","nameEN":"PepGen Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.48.0","shortVersion":"4.48.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"PepGen Inc.(PEPG),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest PepGen Inc.(PEPG) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"PepGen Inc.,PEPG,PepGen Inc.股票,PepGen Inc.股票老虎,PepGen Inc.股票老虎国际,PepGen Inc.行情,PepGen Inc.股票行情,PepGen Inc.股价,PepGen Inc.股市,PepGen Inc.股票价格,PepGen Inc.股票交易,PepGen Inc.股票购买,PepGen Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"PepGen Inc.(PEPG),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest PepGen Inc.(PEPG) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction